TREMFYA (guselkumab), interleukin 23 inhibitor immunosuppressant
DERMATOLOGY - New medicinal product
Opinions on drugs -
Posted on
Dec 18 2018
Reason for request
Inclusion
High clinical benefit for the treatment of severe chronic plaque psoriasis in adults defined by:
failure of at least two treatments including non-biological systemic treatments and light therapy
and an extensive form and/or significant psychosocial impact
but no demonstrated clinical improvement compared to other anti-interleukins.
Insufficient clinical benefit to justify reimbursement for other forms.
TREMFYA has MA for the treatment of moderate to severe plaque psoriasis in adults, requiring systemic treatment.
It has demonstrated its superiority over HUMIRA (adalimumab).
TREMFYA is a second-line systemic treatment to be reserved for adults with severe chronic plaque psoriasis, defined by:
failure (insufficient response, contraindication or intolerance) of at least two treatments including non-biological systemic treatments and light therapy
and an extensive form and/or with significant psychosocial impact.
Clinical Benefit
Substantial |
- |
Insufficient |
Clinical Added Value
no clinical added value |
- |
Therapeutic use
- |